NSE: METROPOLIS | BSE: 542650

Momentum Trap

Download real time

1952.10 11.00 (0.57%)

48.45% Gain from 52W Low

11,254 NSE+BSE Volume

NSE 25 Nov, 2025 3:31 PM (IST)

10,116.2

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Metropolis Healthcare Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for METROPOLIS, BSE:542650 Metropolis Healthcare Ltd.

Search Inside the pdf :

Metropolis Healthcare Ltd.

07 Nov 2025

1952.10

0.57%

Focus shifting towards boosting synergies

Buy: Metropolis Healthcare Ltd.

ICICI Securities Limited

Metropolis delivered a strong beat in operational performance in Q2FY26 led by renewed focus on margin improvement. Metropolis is unlikely to pursue any acquisition in the near term, until the company completes the integration of its recently acquired assets like Core Diagnostics.

Number of FII/FPI investors increased from 171 to 177 in Sep 2025 qtr.

Metropolis Healthcare Ltd.

09 Aug 2025

1952.10

0.57%

Acquisition-led synergies to propel growth

Buy: Metropolis Healthcare Ltd.

Target

ICICI Securities Limited

Metropolis’ Q1FY26 result was largely in line with our expectations. Consolidation of the three recently acquired businesses led to robust revenue growth of ~23% YoY (organic growth of ~13% YoY).

ICICI Securities Limited released a Buy report for Metropolis Healthcare Ltd. with a price target of 2400.0 on 07 Nov, 2025.

Metropolis Healthcare Ltd.

02 Jul 2025

1952.10

0.57%

Growth and margin levers intact

Buy: Metropolis Healthcare Ltd.

Target

Emkay

We met with Ameera Shah, Promoter and Executive Chairperson of Metropolis Healthcare (MHL), to gain insights into management strategy of growing organically (via network expansion) and inorganically (revenue synergies following the integration of recent acquisitions).

Metropolis Healthcare Ltd. is trading above its 200 day SMA of 1842.2

Metropolis Healthcare Ltd.

16 May 2025

1952.10

0.57%

Metropolis Healthcare Ltd.

Neutral: Metropolis Healthcare Ltd.

Target

Keynote Capitals Ltd

Quarterly Update Q4FY25

Number of FII/FPI investors increased from 171 to 177 in Sep 2025 qtr.

Metropolis Healthcare Ltd.

09 Feb 2025

1952.10

0.57%

Metropolis Healthcare | Q3FY25 Result Update

Buy: Metropolis Healthcare Ltd.

Target

Edelweiss

Network expansion to drive growth

Metropolis Healthcar.. has an average target of 2114.50 from 4 brokers.

Metropolis Healthcare Ltd.

06 Feb 2025

1952.10

0.57%

Growth levers adequately in place

Buy: Metropolis Healthcare Ltd.

Recommendation Target

ICICI Securities Limited

Metropolis’ Q3FY25 result was impacted by lower sales from institutional biz (2% impact on revenue) and muted growth in acute ailment tests. In last 4 years, Metropolis has widened its lab network by 68% to 209 labs in 9MFY25.

Metropolis Healthcare Ltd. is trading above its 200 day SMA of 1842.2

Metropolis Healthcare Ltd.

05 Feb 2025

1952.10

0.57%

Soft quarter; outlook remains promising

Buy: Metropolis Healthcare Ltd.

Target

Emkay

MHL’s Q3FY25 EBITDA missed street/our estimates by 9%/4%, with revenue growing 11% YoY driven by B2C revenue improving 15% YoY.

Metropolis Healthcare Ltd. is trading below its 30 day SMA of 1956.2

Metropolis Healthcare Ltd.

11 Dec 2024

1952.10

0.57%

Metropolis Healthcare

Neutral: Metropolis Healthcare Ltd.

Recommendation

Keynote Capitals Ltd

Company Update

ICICI Securities Limited released a Buy report for Metropolis Healthcare Ltd. with a price target of 2400.0 on 07 Nov, 2025.

Metropolis Healthcare Ltd.

10 Dec 2024

1952.10

0.57%

Inorganic foray into non-core markets; scalability key monitorable

Buy: Metropolis Healthcare Ltd.

Emkay

MHL announced its acquisition of Core Diagnostics—an oncology focused diagnostics chain with majority of its revenue derived from North/East India— for Rs2.47bn, thus valuing the company at ~2.24x EV/Sales on FY24 revenue